Overview

• U.S. healthcare e-commerce platform's Q1 net sales fell 58% after FDA ended GLP-1 shortage

• Company posted Q1 net loss and negative adjusted EBITDA as compounded prescription sales declined

• Gross margin improved to 52.1% as B2B prescription sales declined and OTC sales increased

Outlook

• HealthWarehouse.com expects new partnerships and business units to support growth opportunities

• Company continues to invest in proprietary technology to enhance customer experience and scalability

• HealthWarehouse.com expects partnership with healthwords.ai to accelerate operational efficiency and growth

Result Drivers

• FDA REGULATORY CHANGE - Co said Q1 sales decline was mainly due to the FDA ending allowance for compounded GLP-1 prescriptions, reducing B2B prescription revenue

• OTC SALES GROWTH - Co said OTC net sales rose 61.9% year-over-year, mainly from increased marketplace sales

• TECHNOLOGY AND PARTNERSHIPS - Co said it is investing in proprietary technology and formed a new AI partnership to support growth and operational efficiency

Company press release: ID:nBw3VNRlla

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.